A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and Placebo in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 5th largest by enrollment, is one of 3 that started in 2022, is one of 15 in phase 3, and was the 7th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2022.
This study's enrollment of 1,544 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 9th largest by enrollment, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 27th registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at increased risk (AIR) of respiratory syncytial virus (RSV)-lower respiratory tract disease (LRTD), versus adults >=60 YOA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Written or witnessed obtained from the participant prior to performance of any study-specific procedure.
Female participants of childbearing potential may be enrolled in the study, if the participant:
Specific inclusion criteria for participants in the Adults-HA Sub-cohort
Specific inclusion criteria for participants in the Adults-AIR Sub cohort
Participants should be diagnosed with at least 1 of the following medical conditions and have a stable condition (no changes in the treatment or disease severity in the past 3 months):
Other diseases at increased risk for RSV-LRTD disease
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Note: In case an emergency mass vaccination for an unforeseen public health threat is recommended and/or organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly.
Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or administration of long-acting immune modifying treatments or planned administration at any time up to the end of the study.
Prior/Concurrent clinical study experience
Other exclusions Other exclusions for all participants
Other exclusions for Cohort 1
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.
Biological: RSVPreF3 OA investigational vaccine
Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.
Drug: Placebo
Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.
Biological: RSVPreF3 OA investigational vaccine
Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.
Drug: Placebo
Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.
Biological: RSVPreF3 OA investigational vaccine
One dose administered intramuscularly at Day 1.
One dose administered intramuscularly at Day 1.
RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay. The corresponding antibody titers were expressed in Estimated Dilution 60 (ED60) and were measured on blood samples collected from vaccinated subjects. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
RSV-A Neutralization Titers Expressed as Group Seroresponse Rate (SRR) Difference in Healthy Participants Compared to OA-RSV Group
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to 4 (\>=4).
Time frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)
RSV-B Neutralization Titers Expressed as Group GMT in Healthy Participants Compared to OA-RSV Group
Serological assays for the determination of antibodies against RSV-B were performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
RSV-B Neutralization Titers Expressed as Group SRR in Healthy Participants Compared to OA-RSV Group
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.
Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)
RSV-A Neutralization Titers Expressed as Group GMT Titer in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31)
RSV-A Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.
Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)
RSV-B Neutralization Titers Expressed as Group GMT in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group
Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.
Time frame: At 1 month after the RSVPreF3 OA vaccine administration (Day 31)
RSV-B Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.
Time frame: At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)
Percentage of Participants Reporting Each Solicited Administration Site Event (Pain, Redness and Swelling)
Assessed solicited administration site events were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema and swelling symptom = symptom reported with a surface diameter greater than 0 millimeters.
Time frame: During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)
Percentage of Participants Reporting Each Solicited Systemic Event (Fever, Headache, Muscle Pain, Joint Pain, Tiredness)
Assessed solicited systemic events were arthralgia, fatigue, headache, myalgia and fever \[temperature equal to or above (\>=) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.
Time frame: During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)
Percentage of Participants Reporting Any Unsolicited Adverse Events (AEs)
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
Time frame: During the 30-day follow up period after vaccination (vaccine or placebo administered on Day 1)
Percentage of Participants Reporting Any Serious Adverse Events (SAEs) Within 6 Months of Vaccination
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
Time frame: From the day of the vaccination up to 6 months after vaccination (vaccine or placebo administered on Day 1)
Percentage of Participants Reporting Any Onset Potential Immune Mediated Diseases (pIMDs) Within 6 Months of Vaccination
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From the day of the vaccination up to 6 months after vaccination (vaccine or placebo administered on Day 1)
Percentage of Participants Reporting SAEs Related to Study Intervention Administration Within 12 Months of Vaccination
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
Time frame: From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)
Percentage of Participants Reporting pIMDs Related to Study Intervention Administration Within 12 Months of Vaccination
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
Time frame: From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)
Percentage of Participants Reporting Any Fatal SAEs
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
Time frame: From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)
RSV-A Neutralization Titers Expressed as GMT, up to One Month Post-intervention
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.
Time frame: At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)
RSV-A Neutralization Titers Expressed as GMT at Month 6 and Month 12 Post-intervention
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.
Time frame: At 6 months and at 12 months after study intervention administration
RSV-B Neutralization Titers Expressed as GMT, up to One Month Post-intervention
Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.
Time frame: At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)
RSV-B Neutralization Titers Expressed as GMT, at Month 6 and Month 12 Post-intervention
Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.
Time frame: At 6 months and at 12 months after study intervention administration
Frequency of RSVPreF3-specific Cluster of Differentiation (CD)4+ T Cells Expressing at Least 2 Activation Markers up to One Month Post-intervention
Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)
Frequency of RSVPreF3-specific CD4+ T Cells Expressing at Least 2 Activation Markers, at Month 6 and Month 12 Post-intervention
Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At 6 months and at 12 months after study intervention administration
Frequency of RSVPreF3-specific CD8+ T Cells Expressing at Least 2 Activation Markers, up to One Month Post-intervention
Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)
Frequency of RSVPreF3-specific CD8+ T Cells Expressing at Least 2 Activation Markers, at Month 6 and Month 12
Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
Time frame: At 6 months and at 12 months after study intervention administration
Out of 1544 participants enrolled in this study, 1534 participants received at least one study intervention, from which 1 participant in OA-RSV group received placebo instead of RSVPreF3 OA vaccine and was excluded from the group. Therefore, the Exposed set included 1533 participants.
| Milestone | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Started | 383 | 192 | 386 | 191 | 381 |
| Completed | 363 | 184 | 369 | 180 | 369 |
| Not completed | 20 | 8 | 17 | 11 | 12 |
| Withdrew: Lost to follow-up | 13 | 1 | 7 | 3 | 4 |
| Withdrew: Consent withdrawal, not due to a (s)ae | 4 | 6 | 4 | 2 | 7 |
| Withdrew: Other | 2 | 0 | 2 | 2 | 0 |
| Withdrew: Migrated / moved from the study area | 1 | 1 | 0 | 3 | 1 |
| Withdrew: Adverse event requiring expedited reporting | 0 | 0 | 4 | 1 | 0 |
Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay. The corresponding antibody titers were expressed in Estimated Dilution 60 (ED60) and were measured on blood samples collected from vaccinated subjects. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titer | Adults HA-RSV Group | OA-RSV Group |
|---|---|---|
| RSV-A Neutralization Titers Expressed as Group Geometric Mean Titer (GMT) in Healthy Participants Compared to OA-RSV Group | 7906.0 (7178.1 to 8707.7) | 7518.9 (6843.2 to 8261.3) |
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to 4 (\>=4).
| Percentage of participants | Adults HA-RSV Group | OA-RSV Group |
|---|---|---|
| RSV-A Neutralization Titers Expressed as Group Seroresponse Rate (SRR) Difference in Healthy Participants Compared to OA-RSV Group | 82.8 (78.3 to 86.8) | 80.2 (75.6 to 84.3) |
Serological assays for the determination of antibodies against RSV-B were performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titer | Adults HA-RSV Group | OA-RSV Group |
|---|---|---|
| RSV-B Neutralization Titers Expressed as Group GMT in Healthy Participants Compared to OA-RSV Group | 9024.8 (8240.8 to 9883.3) | 8070.3 (7385.2 to 8819.1) |
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.
| Percentage of participants | Adults HA-RSV Group | OA-RSV Group |
|---|---|---|
| RSV-B Neutralization Titers Expressed as Group SRR in Healthy Participants Compared to OA-RSV Group | 78.2 (73.3 to 82.6) | 74.3 (69.3 to 78.8) |
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titer | Adults AIR-RSV Group | OA-RSV Group |
|---|---|---|
| RSV-A Neutralization Titers Expressed as Group GMT Titer in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group | 8925.1 (8117.9 to 9812.6) | 7460.7 (6786.8 to 8201.5) |
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.
| Percentage of participants | Adults AIR-RSV Group | OA-RSV Group |
|---|---|---|
| RSV-A Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group | 86.8 (82.8 to 90.2) | 80.2 (75.6 to 84.3) |
Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR-RSV and OA-RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan.
| Titer | Adults AIR-RSV Group | OA-RSV Group |
|---|---|---|
| RSV-B Neutralization Titers Expressed as Group GMT in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group | 10048.6 (9218.4 to 10953.5) | 8073.4 (7406.4 to 8800.4) |
The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) \>=4.
| Percentage of participants | Adults AIR-RSV Group | OA-RSV Group |
|---|---|---|
| RSV-B Neutralization Titers Expressed as Group SRR in Participants at Increased Risk of RSV-LRTD (Adults-AIR-RSV Group) Compared to OA-RSV Group | 81.6 (77.1 to 85.5) | 74.3 (69.3 to 78.8) |
Assessed solicited administration site events were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema and swelling symptom = symptom reported with a surface diameter greater than 0 millimeters.
| Percentage of participants | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Erythema | 11.9 (8.8 to 15.6) | 0.5 (0.0 to 2.9) | 14.5 (11.1 to 18.5) | 0.5 (0.0 to 2.9) | 12.1 (9.0 to 15.9) |
| Pain | 76.7 (72.1 to 80.8) | 10.5 (6.5 to 15.7) | 75.2 (70.5 to 79.5) | 14.3 (9.6 to 20.1) | 61.2 (56.1 to 66.1) |
| Swelling | 9.3 (6.6 to 12.7) | 1.0 (0.1 to 3.7) | 11.6 (8.6 to 15.3) | 0.5 (0.0 to 2.9) | 7.7 (5.2 to 10.8) |
Assessed solicited systemic events were arthralgia, fatigue, headache, myalgia and fever \[temperature equal to or above (\>=) 38 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.
| Percentage of participants | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Arthralgia | 26.0 (21.6 to 30.7) | 5.8 (2.9 to 10.1) | 20.8 (16.9 to 25.3) | 10.0 (6.1 to 15.2) | 12.9 (9.7 to 16.7) |
| Fatigue | 44.0 (39.0 to 49.2) | 17.3 (12.2 to 23.4) | 36.1 (31.3 to 41.2) | 19.5 (14.1 to 25.8) | 24.0 (19.8 to 28.6) |
| Headache | 35.8 (31.0 to 40.9) | 16.8 (11.8 to 22.8) | 27.7 (23.3 to 32.5) | 17.4 (12.3 to 23.5) | 21.1 (17.1 to 25.6) |
| Myalgia | 39.3 (34.3 to 44.4) | 5.8 (2.9 to 10.1) | 32.5 (27.8 to 37.4) | 14.2 (9.6 to 20.0) | 21.4 (17.4 to 25.8) |
| Fever | 3.7 (2.0 to 6.2) | 1.0 (0.1 to 3.7) | 2.6 (1.3 to 4.8) | 1.1 (0.1 to 3.8) | 1.6 (0.6 to 3.4) |
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
| Percentage of participants | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Percentage of Participants Reporting Any Unsolicited Adverse Events (AEs) | 13.6 (10.3 to 17.4) | 13.5 (9.0 to 19.2) | 15.3 (11.8 to 19.3) | 10.5 (6.5 to 15.7) | 16.3 (12.7 to 20.4) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
| Percentage of participants | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Percentage of Participants Reporting Any Serious Adverse Events (SAEs) Within 6 Months of Vaccination | 0.8 (0.2 to 2.3) | 2.1 (0.6 to 5.2) | 3.9 (2.2 to 6.3) | 2.1 (0.6 to 5.3) | 2.4 (1.1 to 4.4) |
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Percentage of participants | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Percentage of Participants Reporting Any Onset Potential Immune Mediated Diseases (pIMDs) Within 6 Months of Vaccination | 0 (0 to 1.0) | 0 (0 to 1.9) | 1.0 (0.3 to 2.6) | 0.5 (0.0 to 2.9) | 0.8 (0.2 to 2.3) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
| Percentage of participants | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Percentage of Participants Reporting SAEs Related to Study Intervention Administration Within 12 Months of Vaccination | 0 (0 to 1.0) | 0 (0 to 1.9) | 0 (0 to 1.0) | 0 (0.0 to 1.9) | 0.3 (0.0 to 1.5) |
pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.
| Percentage of participants | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Percentage of Participants Reporting pIMDs Related to Study Intervention Administration Within 12 Months of Vaccination | 0 (0 to 1.0) | 0 (0 to 1.9) | 0 (0 to 1.0) | 0 (0.0 to 1.9) | 0.3 (0.0 to 1.5) |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.
| Percentage of participants | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Percentage of Participants Reporting Any Fatal SAEs | 0 (0 to 1.0) | 0 (0 to 1.9) | 1.0 (0.3 to 2.6) | 0.5 (0.0 to 2.9) | 0 (0 to 1.0) |
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.
| Titer | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Day 1 | 768.8 (704.7 to 838.9) | 772.0 (677.9 to 879.1) | 779.5 (725.5 to 837.6) | 729.8 (648.6 to 821.0) | 775.7 (709.9 to 847.5) |
| Day 31 | 7925.4 (7125.6 to 8815.0) | 796.9 (696.4 to 912.0) | 8804.1 (7953.3 to 9746.0) | 774.7 (683.0 to 878.6) | 7498.8 (6759.5 to 8319.1) |
Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.
| Titer | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Month 6 | 3850.7 (3448.6 to 4299.7) | 849.6 (748.9 to 963.9) | 3980.6 (3608.6 to 4391.1) | 854.2 (756.2 to 965.0) | 3846.3 (3469.7 to 4263.7) |
| Month 12 | 3192.9 (2855.1 to 3570.7) | 965.1 (846.8 to 1099.9) | 3075.1 (2772.2 to 3411.0) | 971.8 (864.6 to 1092.4) | 3080.4 (2764.8 to 3432.0) |
Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.
| Titer | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Day 1 | 1091.1 (1000.3 to 1190.2) | 1197.7 (1055.7 to 1358.8) | 1141.4 (1050.5 to 1240.0) | 1167.2 (1035.0 to 1316.1) | 1109.1 (1020.6 to 1205.3) |
| Day 31 | 8971.9 (8109.6 to 9925.8) | 1145.3 (1012.4 to 1295.5) | 9943.0 (9035.8 to 10941.4) | 1141.8 (1007.4 to 1294.2) | 8169.3 (7412.6 to 9003.3) |
Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA-RSV, Adults HA-Placebo, Adult AIR-RSV, Adult AIR-Placebo and OA-RSV groups.
| Titer | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Month 6 | 3880.7 (3488.4 to 4317.0) | 1003.2 (875.5 to 1149.4) | 4020.8 (3635.9 to 4446.5) | 942.1 (825.4 to 1075.3) | 3710.4 (3361.0 to 4096.1) |
| Month 12 | 3562.8 (3176.0 to 3996.7) | 1218.6 (1038.8 to 1429.5) | 3669.9 (3287.1 to 4097.3) | 1153.5 (996.6 to 1335.2) | 3527.7 (3177.5 to 3916.4) |
Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD4+ T cells/million cells | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Day 1 | 102.7 ± 0.9 | 125.6 ± 0.9 | 161.5 ± 0.6 | 114.7 ± 0.9 | 111.3 ± 0.9 |
| Day 31 | 1282.5 ± 0.4 | 167.7 ± 0.8 | 1043.6 ± 0.6 | 131.9 ± 0.8 | 1016.9 ± 0.8 |
Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD4+ T cells/million cells | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Month 6 | 825.6 ± 0.3 | 140.5 ± 0.8 | 662.9 ± 0.3 | 39.2 ± 1.0 | 763.5 ± 0.5 |
| Month 12 | 492.0 ± 0.6 | 175.8 ± 0.5 | 335.5 ± 0.7 | 59.4 ± 1.0 | 414.1 ± 0.7 |
Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD8+ T cells/million cells | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Day 1 | 10.1 ± 1.1 | 6.0 ± 0.9 | 15.5 ± 1.0 | 10.8 ± 1.1 | 12.0 ± 1.0 |
| Day 31 | 15.2 ± 1.1 | 11.9 ± 1.1 | 18.1 ± 1.1 | 4.8 ± 1.1 | 12.0 ± 1.2 |
Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.
| CD8+ T cells/million cells | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Month 6 | 23.1 ± 1.0 | 12.2 ± 1.1 | 27.6 ± 1.0 | 14.0 ± 1.0 | 14.8 ± 1.1 |
| Month 12 | 15.2 ± 1.0 | 23.0 ± 0.9 | 16.2 ± 1.0 | 6.6 ± 1.1 | 14.9 ± 1.0 |
Collected over Solicited AEs were collected from Day 1 (day of vaccination) up to Day 4 post-dose. Unsolicited AEs were collected from Day 1 up to Day 30 post-dose. SAEs and pIMDs were collected from Day 1 up to Month 6 post dose-administration. Related SAEs, related pIMDs and fatal SAEs were collected from Day 1 up to study end (Month 12).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adults HA-RSV Group | 0/383 (0%) | 3/383 (0.8%) | 325/383 (84.9%) |
| Adults HA-Placebo Group | 0/192 (0%) | 4/192 (2.1%) | 76/192 (39.6%) |
| Adults AIR-RSV Group | 1/386 (0.3%) | 15/386 (3.9%) | 318/386 (82.4%) |
| Adults AIR-Placebo Group | 1/191 (0.5%) | 4/191 (2.1%) | 74/191 (38.7%) |
| OA-RSV Group | 0/381 (0%) | 9/381 (2.4%) | 279/381 (73.2%) |
| Event | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/383 | 0/192 | 3/386 | 0/191 | 2/381 |
| PericarditisCardiac disorders | 0/383 | 0/192 | 0/386 | 1/191 | 0/381 |
| COVID-19Infections and infestations | 0/383 | 0/192 | 0/386 | 1/191 | 0/381 |
| CellulitisInfections and infestations | 0/383 | 0/192 | 1/386 | 1/191 | 0/381 |
| OsteomyelitisInfections and infestations | 0/383 | 0/192 | 0/386 | 1/191 | 0/381 |
| DeathGeneral disorders | 0/383 | 0/192 | 1/386 | 1/191 | 0/381 |
| Abscess oralInfections and infestations | 0/383 | 1/192 | 0/386 | 0/191 | 0/381 |
| ObesityMetabolism and nutrition disorders | 0/383 | 1/192 | 1/386 | 0/191 | 0/381 |
| DepressionPsychiatric disorders | 0/383 | 1/192 | 1/386 | 0/191 | 0/381 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/383 | 1/192 | 0/386 | 0/191 | 0/381 |
| Event | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group |
|---|---|---|---|---|---|
| Administration site painGeneral disorders | 289/383 | 20/192 | 285/386 | 27/191 | 232/381 |
| FatigueGeneral disorders | 166/383 | 34/192 | 136/386 | 37/191 | 92/381 |
| MyalgiaMusculoskeletal and connective tissue disorders | 149/383 | 12/192 | 123/386 | 27/191 | 83/381 |
| HeadacheNervous system disorders | 137/383 | 34/192 | 106/386 | 33/191 | 81/381 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 101/383 | 12/192 | 80/386 | 19/191 | 50/381 |
| Injection site erythemaGeneral disorders | 40/383 | 1/192 | 55/386 | 1/191 | 42/381 |
| Administration site erythemaGeneral disorders | 40/383 | 1/192 | 55/386 | 1/191 | 42/381 |
| Injection site swellingGeneral disorders | 32/383 | 2/192 | 43/386 | 1/191 | 25/381 |
| Administration site swellingGeneral disorders | 32/383 | 0/192 | 3/386 | 0/191 | 0/381 |
| PyrexiaGeneral disorders | 14/383 | 2/192 | 11/386 | 3/191 | 7/381 |
| Age, Continuous(YEARS) | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group | Total |
|---|---|---|---|---|---|---|
| Mean | 54.8 ± 2.8 | 54.7 ± 2.8 | 55.3 ± 2.8 | 55.6 ± 2.8 | 64.1 ± 2.9 | 58.6 ± 7.5 |
| Sex: Female, Male(Participants) | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group | Total |
|---|---|---|---|---|---|---|
| Female | 221 | 119 | 186 | 85 | 188 | 799 |
| Male | 162 | 73 | 200 | 106 | 193 | 734 |
| Ethnicity (NIH/OMB)(Participants) | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group | OA-RSV Group | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 48 | 23 | 63 | 35 | 50 | 219 |
| Not Hispanic or Latino | 335 | 168 | 323 | 156 | 330 | 1312 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 2 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Oct 2022 to primary completion in Mar 2023, 4 months.
Results were first posted in May 2024, 1 year 2 months after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 4 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →